Results showed non-inferiority for linagliptin vs glimepiride in meeting its primary endpoint of time to first occurrence of CV death, non-fatal myocardial infarction or non-fatal stroke.
According to a final recommendation statement released by the US Preventive Services Task Force (USPSTF), clinicians should offer preexposure prophylaxis (PrEP) with effective antiretroviral therapy to patients at high risk of HIV acquisition (Grade A recommendation).
The FDA has approved Emgality (galcanezumab-gnlm; Lilly) for injection for the treatment of episodic cluster headache in adults.
The FDA has accepted for review the New Drug Application for an investigational triple combination tablet for the treatment of adults with type 2 diabetes.
Individuals treated preventively with Xofluza were significantly less likely to develop influenza after exposure to an infected household member, according to data from the phase 3 BLOCKSTONE study.
